Home > Healthcare & Medical Devices > Leuprolide Acetate Market

Leuprolide Acetate Market Size, By Application (Cancer [Prostate Cancer, Breast Cancer, Cervix Uteri, Ovary Cancer, Testis], Radical Prostatectomy, Central Precocious Puberty, Endometriosis, Hormone Therapy, Uterine Fibroids), By Product Form (Lyophilized Powder, Pre-Filled Syringes, Vials), By Route Of Administration (Intradermal, Intramuscular, Subcutaneous), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Regional Outlook, Industry Analysis Report, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI5432
  • Published Date: Feb 2023
  • Report Format: PDF

Industry Statistics

Leuprolide Acetate Market size valuation was recorded at over USD 2 billion in 2022 and is estimated to grow at a 6% CAGR between 2023 and 2032 driven by soaring awareness regarding the benefits of leuprolide acetate injections.

Leuprolide Acetate Market

Get more details on this report - Request Free Sample PDF

Rising incidences of cancer globally are set to fuel market progress. For instance, Europe constitutes nearly a quarter of all cancer diagnoses in the world. According to estimations, the four most prevalent cancer types in Europe account for over 50% of all cancer diagnoses, with breast cancer accounting for 13.1%, colorectal cancer for 12.9%, lung cancer for approximately 11.8%, and prostate cancer for nearly 11.7%. This is propelling the demand for leuprolide acetate medications for cancer treatment in the coming years.

Furthermore, the growing female population base suffering from endometriosis is also promoting product use. According to an OASH report, endometriosis affects approximately 176 million women worldwide and 11% of American women between the ages of 15 to 44. A study based on leuprolide acetate’s impact on endometriosis patients post hysterectomy and BSO concluded that these drugs aided in complete preoperative pain relief after the completion of procedures.

Unfavorable price control schemes may restrain industry progression

Strict drug price-control policies are restraining leuprolide acetate market expansion. Unfavorable medicine price caps and control measures adversely impact leuprolide acetate drugs as they standardize medications and biopharmaceutical costs, which, in turn, hinders business growth. According to the National Bureau of Economic Research, drug price control schemes can lower prescription prices in the United States by 40 to 50%, which would result in a 30 to 60% reduction in R&D funding and programs. Nonetheless, the increasing prevalence of cancer is likely to boost product size.

Low patient risk and investment benefits to push pre-filled syringes segment demand

Global Leuprolide Acetate Market Share, By Product Form

Get more details on this report - Request Free Sample PDF

Based on product form, the leuprolide acetate market is categorized into lyophilized powder, vials, and pre-filled syringes. The pre-filled syringes segment was worth over USD 910 million in 2022. The rising consumer demand due to reduced patient risk and the growing knowledge pertaining to the advantages of prefilled syringes, including low tie and money investment, is pushing doctors to utilize pre-filled syringes, which is foreseen to bolster product uptake. To cite an instance, in April 2022, the Lupron Depot 7.5 mg was made available in a prefilled dual-chamber syringe for monthly intramuscular injection that reported less than 5% of patient reactions without any casualties in a clinical trial.

Growing occurrences of cancer to define the industry landscape

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market for leuprolide acetate was valued at more than USD 2 billion in 2022 and is set to progress at a 6% CAGR between 2023 and 2032 owing to the growing female population suffering from endometriosis and cancer as well as the soaring awareness regarding the benefits of leuprolide acetate injections.

The cancer application segment held more than 25% revenue share in 2022 and is projected to observe notable growth through 2032 due to the global rise in cancer cases which is increasing the demand for leuprolide acetate drugs for treatment.

The pre-filled syringes segment surpassed USD 910 million in revenue in 2022 as a result of rising consumer demand due to reduced patient risk and growing knowledge pertaining to the advantages of pre-filled syringes.

North America leuprolide acetate market held more than 39% market share in 2022 and is anticipated to record sizable progress over 2023-2032 on account of the favorable landscape for product approval from regulatory bodies, such as the U.S. FDA, in the region.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 25
  • Tables & Figures: 363
  • Countries covered: 32
  • Pages: 320

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount